Company news
HLS Therapeutics, Inc. news in 2019
HLS Therapeutics, Inc.'s news releases, calls and decks from 2019, newest first.
HLS Therapeutics Announces Health Canada Approval for Vascepa® to Reduce the Risk of Cardiovascular Events
December 31, 2019
HLS Therapeutics Reports on U.S. FDA Advisory Committee Recommendation for Vascepa
November 15, 2019
HLS Therapeutics Announces Q3 2019 Financial Results
November 7, 2019
HLS Therapeutics to Host Q3 2019 Financial Results Conference Call
October 24, 2019
HLS Therapeutics announces Health Canada grants medical device license for White Blood Cell Point-of-Care Device to be marketed as CSAN® PRONTO(TM)
October 17, 2019
HLS Therapeutics Announces Q2 2019 Financial Results
August 8, 2019
HLS Therapeutics to Host Q2 2019 Financial Results Conference Call
July 25, 2019
HLS Therapeutics Announces Closing of $50 Million Bought Deal Offering
June 5, 2019
HLS Therapeutics to Present at Two Upcoming Conferences
May 30, 2019
HLS Therapeutics Announces $43,500,000 Million Bought Deal Offering
May 14, 2019
HLS Therapeutics Announces Q1 2019 Financial Results
May 9, 2019
HLS Therapeutics Files New Drug Submission for Vascepa® in Canada
April 29, 2019
HLS Therapeutics to Host Q1 2019 Financial Results Conference Call
April 25, 2019
HLS Therapeutics to Present at the 2019 Bloom Burton & Co. Healthcare Investor Conference
April 23, 2019
HLS Therapeutics Granted Priority Review Status from Health Canada for Vascepa®
March 29, 2019
HLS Therapeutics Announces Q4 and Year-End 2018 Financial Results
March 21, 2019
HLS Therapeutics Inc. Opens the Market
March 20, 2019
HLS Therapeutics Announces Vascepa® (icosapent ethyl) Showed 30% Reduction in Total Cardiovascular Events Including Recurrent Events in REDUCE-IT(TM)
March 19, 2019
HLS Therapeutics Announces High Risk of Atherosclerotic Cardiovascular Events Projected in People with Elevated Triglycerides Without Established Atherosclerotic Cardiovascular Disease
March 19, 2019
HLS Therapeutics Licenses and Files 'Athelas One' Point-of-Care Device
March 14, 2019
HLS Therapeutics to Host 2018 Fourth Quarter and Year-End Financial Results Conference Call
March 7, 2019
HLS Therapeutics to Present at the 8th Annual SVB Leerink Global Healthcare Conference
February 19, 2019
HLS Therapeutics Announces Graduation to the Toronto Stock Exchange
February 6, 2019
HLS Therapeutics Receives Conditional Approval to Graduate to the Toronto Stock Exchange
January 29, 2019
Decks in 2019
- Q2 2019 Earnings Presentation
Earnings · 22 slides · Aug 8, 2019